Artiva Biotherapeutics, Inc. (ARTV) Ownership
ARTV ownership summary
as of October 17, 2026- Institutions
- 84.3% of shares outstanding
- Insiders
- 15.10% of shares outstanding
- Shares outstanding
- 48.9M
- Float
- 19.5M shares available to trade
- Short interest
- 9.26% 2.3M shares short
- Days to cover
- 4.88 short interest up 11.2% vs prior month
- Institutions 84.31%
- Insiders 15.10%
- Other investors 0.60%
ARTV top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | RA Capital Management, LLC | 36.73% | 18.0M | $105.0M | +8.1M (+82.2%) | June 30, 2026 |
| 2 | Viking Global Investors LP | 5.33% | 2.6M | $15.2M | +2.6M (0.0%) | June 30, 2026 |
| 3 | Blackstone Inc | 4.92% | 2.4M | $14.1M | +2.4M (0.0%) | June 30, 2026 |
| 4 | 5AM Venture Management, LLC | 4.81% | 2.4M | $13.8M | — | June 30, 2026 |
| 5 | VR Adviser, LLC | 4.18% | 2.0M | $12.0M | +434,027 (+27.0%) | June 30, 2026 |
| 6 | Franklin Templeton Inc | 4.09% | 2.0M | $11.7M | +1.5M (+283.8%) | June 30, 2026 |
| 7 | Caligan Partners LP | 3.55% | 1.7M | $10.2M | +1.7M (0.0%) | June 30, 2026 |
| 8 | Vanguard Capital Management, LLC | 2.01% | 982K | $5.7M | +774,129 (+372.7%) | June 30, 2026 |
| 9 | Samsara BioCapital, LLC | 1.95% | 955K | $5.6M | +954,861 (0.0%) | June 30, 2026 |
| 10 | Blue Owl Capital Holdings LP | 1.79% | 875K | $5.1M | +874,542 (0.0%) | June 30, 2026 |
| 11 | Propel Bio Management LLC | 1.42% | 696K | $4.1M | +550,067 (+375.8%) | June 30, 2026 |
| 12 | BlackRock Inc | 1.42% | 695K | $4.1M | +481,338 (+225.6%) | June 30, 2026 |
| 13 | Citadel Advisors Llc | 1.25% | 609K | $3.6M | +593,506 (+3,739.8%) | June 30, 2026 |
| 14 | Nantahala Capital Management, LLC | 1.23% | 600K | $3.5M | +600,000 (0.0%) | June 30, 2026 |
| 15 | SILVERARC CAPITAL MANAGEMENT, LLC | 1.07% | 525K | $3.1M | +525,000 (0.0%) | June 30, 2026 |
| 16 | Geode Capital Management, LLC | 0.72% | 354K | $2.1M | +252,150 (+247.9%) | June 30, 2026 |
| 17 | BOOTHBAY FUND MANAGEMENT, LLC | 0.64% | 314K | $1.8M | +314,375 (0.0%) | June 30, 2026 |
| 18 | Revelation Capital Management, LLC | 0.61% | 299K | $1.8M | — | June 30, 2026 |
| 19 | Alyeska Investment Group, L.P. | 0.56% | 274K | $1.6M | +173,615 (+173.6%) | June 30, 2026 |
| 20 | Longwood Capital Partners LLC | 0.53% | 260K | $1.5M | +260,416 (0.0%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 18 holders added 23.1M shares and 0 cut 0.
ARTV top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Franklin Biotechnology Discv A(acc)USD | 1.92% | 940K | $5.5M | — | August 31, 2026 |
| 2 | Vanguard MStar Total Stk Mkt Idx Invest | 1.43% | 700K | $4.1M | — | August 31, 2026 |
| 3 | Franklin Biotechnology Discovery A | 1.11% | 542K | $3.2M | — | August 31, 2026 |
| 4 | iShares Russell 2000 ETF | 0.98% | 481K | $2.8M | −5,568 (−1.1%) | September 30, 2026 |
| 5 | Franklin Small Cap Growth Adv | 0.93% | 456K | $2.7M | — | August 31, 2026 |
| 6 | iShares Russell 2000 Value ETF | 0.26% | 129K | $751,994 | +194 (+0.2%) | September 30, 2026 |
| 7 | Fidelity Extended Market Index | 0.24% | 115K | $673,715 | +1,115 (+1.0%) | August 31, 2026 |
| 8 | Simplify Propel Opportunities ETF | 0.21% | 101K | $592,927 | — | September 30, 2026 |
| 9 | iShares Micro-Cap ETF | 0.12% | 61K | $355,703 | −419 (−0.7%) | September 30, 2026 |
| 10 | Fidelity Small Cap Index | 0.11% | 52K | $301,608 | +1,166 (+2.3%) | July 31, 2026 |
| 11 | iShares Russell 2000 Growth ETF | 0.10% | 50K | $293,301 | −63 (−0.1%) | September 30, 2026 |
| 12 | Bridgeway Ultra-Small Company | 0.10% | 50K | $292,500 | +50,000 (0.0%) | June 30, 2026 |
| 13 | A4Investments SICAV SIF ACCI IlanaA2EURH | 0.10% | 50K | $292,500 | +25,000 (+100.0%) | September 30, 2026 |
| 14 | Vifag 2002 SICAV | 0.10% | 50K | $292,500 | — | July 31, 2026 |
| 15 | Fidelity Total Market Index | 0.10% | 50K | $290,844 | — | August 31, 2026 |
| 16 | Fidelity Series Total Market Index | 0.07% | 36K | $211,138 | −2,942 (−7.5%) | August 31, 2026 |
| 17 | EA Bridgeway Ultra-Small Company Mkt ETF | 0.07% | 35K | $202,024 | — | September 30, 2026 |
| 18 | Fidelity Nasdaq Composite Index | 0.06% | 29K | $171,364 | — | August 31, 2026 |
| 19 | DFA US Micro Cap I | 0.06% | 27K | $160,442 | — | August 31, 2026 |
| 20 | Vanguard Russell 2000 ETF | 0.05% | 27K | $155,312 | +480 (+1.8%) | August 31, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
ARTV insider transactions
latest 4| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-15 | Fred Aslan | Sell | $6.00 | 3,187 | $19,122 |
| 2025-11-17 | Fred Aslan | Sell | $3.38 | 6,375 | $21,548 |
| 2025-10-17 | Fred Aslan | Sell | $6.00 | 25,500 | $153,000 |
| 2025-08-15 | Fred Aslan | Sell | $2.73 | 25,500 | $69,615 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
ARTV shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns ARTV
Institutional investors own 84.3% of Artiva Biotherapeutics's shares and insiders 15.10%. The largest holder is RA Capital Management, LLC with 36.73% of the shares (18.0M), as of June 30, 2026. Among the top 20 institutions, 18 added shares and 0 reduced their stake in the latest filings. Short interest is 9.26% of the float, or 4.88 days of average trading volume. The share count rose 19.6% since 2023.
Related: ARTV analyst forecast, ARTV key metrics. See the ARTV stock overview for the latest quote and news.
ARTV ownership FAQ
Who owns the most Artiva Biotherapeutics stock?
The largest shareholders of Artiva Biotherapeutics are RA Capital Management, LLC (36.73%), Viking Global Investors LP (5.33%), Blackstone Inc (4.92%), 5AM Venture Management, LLC (4.81%), VR Adviser, LLC (4.18%).
What percentage of Artiva Biotherapeutics is owned by institutions?
Institutions hold 84.3% of Artiva Biotherapeutics's shares outstanding; insiders hold 15.10%.
Which funds own Artiva Biotherapeutics?
The largest fund holders of Artiva Biotherapeutics are Franklin Biotechnology Discv A(acc)USD (1.92%), Vanguard MStar Total Stk Mkt Idx Invest (1.43%), Franklin Biotechnology Discovery A (1.11%), iShares Russell 2000 ETF (0.98%), Franklin Small Cap Growth Adv (0.93%).
What is Artiva Biotherapeutics's short interest?
2.3M shares of Artiva Biotherapeutics were sold short, 9.26% of the float; at the average daily volume it would take 4.88 days to cover.
Are insiders buying or selling Artiva Biotherapeutics?
Of the latest 4 reported insider transactions in Artiva Biotherapeutics (since August 15, 2025), 0 were purchases and 4 were sales.
How many shares of Artiva Biotherapeutics are outstanding?
Artiva Biotherapeutics has 48.9M shares outstanding, of which 19.5M are in the public float.